Raaj Medisafe India Reports Strong Revenue Growth, Profit Decline in FY26

Revenue from operations reached ₹80.01 crore for the year ended March 31, 2026, up 28.18% from ₹62.42 crore in FY25.
Profit for the period stood at ₹1.81 crore, a sharp decrease from ₹6.13 crore in the previous year.

Reader Takeaway: Hygiene division shines with revenue growth, but rising costs and tax hit annual profit.

What Just Happened

Raaj Medisafe India Limited announced its standalone financial results for the year ended March 31, 2026. The company saw its revenue from operations increase by 28.18% to ₹80.01 crore. However, its profit for the period saw a significant decline of 70.47%, falling to ₹1.81 crore from ₹6.13 crore in FY25. Finance costs also rose substantially by 86.21% to ₹3.96 crore.

The company also completed a preferential issue, raising ₹18.01 crore by allotting 3,275,000 equity shares at ₹55 per share. Authorised share capital was increased to ₹18 crore.

Why This Matters

The strong revenue growth, particularly from the Hygiene division, signals market acceptance and expansion potential. However, the drastic fall in profitability despite revenue increases raises concerns about cost management and the impact of rising finance costs and taxation. A net loss of ₹3.23 crore in the fourth quarter, despite a pre-tax profit, highlights the sensitivity of earnings to tax expenses.

The Backstory

In the previous fiscal year (FY25), Raaj Medisafe India had reported higher profits and lower finance costs. The company has been focused on expanding its production capacity. The recent preferential issue aimed to fund these expansion plans and provide working capital.

What Changes Now

With the capital infusion, the company is better positioned to execute its expansion plans. Investors will be closely watching how the increased capacity impacts future revenues and profitability, and whether the company can manage its rising finance costs and tax liabilities more effectively.

Risks to Watch

Rising finance costs are directly eating into profits. The volatility in net profit due to tax expenses, particularly the Q4 loss, indicates a potential risk to earnings stability. The company needs to demonstrate improved operational efficiency to counter these cost pressures.

Peer Comparison

While specific peer data for FY26 is not provided in the filing, the company operates in the medical devices and hygiene products sector. Growth in the hygiene segment is a positive trend across the broader industry.

Context Metrics (Time-bound)

• Revenue from Operations: FY2026: ₹80.01 crore (FY2025: ₹62.42 crore)
• Profit for the Period: FY2026: ₹1.81 crore (FY2025: ₹6.13 crore)
• Finance Costs: FY2026: ₹3.96 crore (FY2025: ₹2.13 crore)
• Q4 FY26 Net Loss: ₹3.23 crore
• Preferential Issue: ₹18.01 crore raised, 3,275,000 shares at ₹55 each.

What to Track Next

Investors should monitor the company's future quarterly results, focusing on revenue growth drivers, cost management strategies, the impact of increased finance costs, and the effective management of tax liabilities. The success of the capacity expansion project in translating to improved margins will be key.